Suggestions(1)
Exact(5)
Over half of the countries in all different income levels had all components for 1st line therapy of HR+/HER2- and HR-/ HER2- types of advanced breast cancer as essential medicines (Fig. 3a).
The retrospective starting point of the study (i.e. the date the first patient received the first cycle of trastuzumab based 1st line therapy) was June 2001.
The proportion of countries in which all components of 1st line therapy were selected in the NEMLs for different types of advanced breast cancer was not significantly different across the 3 income level categories (p = 0.410).
Regular QOL monitoring even outside the hospital setting has also been suggested by the results of different studies investigating the concept of maintenance treatment in 1st line therapy of patients with metastatic NSCLC.
For variables collected throughout the study, such as serious adverse events (complications) or the time to therapeutic failure of the 1st line therapy (TTF), the structure of the bar chart varied from one pattern to another.
Similar(54)
Thirteen patients switched to second line ART after a median of 16.8 months (IQR 15.6 to 24.1) on first line therapy.
49 patients (56%) received RFA after 1st line, 31 (36%) after 2nd line, and 8 (9%) after 3rd line therapy.
Twenty-five were treated for active disease (5 first-line therapy, 20 salvage therapy) and 15 for remission maintenance.
Patients must have received ≥3 prior regimens, must be responsive to at least 1 line of therapy, and be refractory to their most recent therapy.
All regimens are first line therapies, except regimens 3, 4, 7 and 18 to 22 which are second line therapies; 6, 10, 17, 21 are third line therapies and 15 is a fourth line therapy.
Therefore, we defined tumours >300 mm as clinically progressing, and used this threshold to add INC280 as "second line" therapy.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com